New data from ATAC, one of the world's largest and longest-running studies in postmenopausal women with early breast cancer, reinforce that anastrozole can help many more women live cancer-free, for longer.
Ads by Google
Patent 7,309,486 issued to NexGen Biomedical discloses a better way of using Genentech's drug Herceptin against breast cancer. The patent discloses that today's practice of concurrent administration of Herceptin with conventional phase specific chemotherapy results in antagonistic action between the two classes of drugs. In later stage cancers, these protocols only increase median survival by several months.
Study demonstrated the value of Breast-Specific Gamma Imaging (BSGI) as a strong adjunctive imaging modality to mammography and breast ultrasound.
A combination of a targeted therapy and chemotherapy shrank metastatic brain tumors by at least 50 percent in one-fifth of patients with aggressive HER2-positive breast cancer.
Avastin (bevacizumab) can proceed to be tested after breast cancer surgery in combination with anthracycline containing regimens. These findings pave the way for Avastin's use as a curative treatment for women with this devastating disease.
PreMD data shows increased reactivity in nipple aspirate fluid from breast cancer patients. The abstract, entitled, 'Galactose oxidase Schiff's (GOS) reactivity is higher in nipple aspirate fluid from cancerous breasts than from healthy patients,' was presented by Dr. Anees B. Chagpar from the University of Louisville.
"This is a very interesting study that could influence how testing for breast cancer is performed in the future," said Brent Norton, president and chief executive officer of PreMD Inc. "With additional research, our
Study suggests that surgical treatment for breast asymmetry (disproportionate breast size) provides an improvement in the quality of life and self-esteem of patients. Breast asymmetry is not uncommon in women; in fact, few women have perfectly symmetrical breasts.
By manipulating highly specific gene-regulating molecules called microRNAs, scientists at Cold Spring Harbor Laboratory (CSHL) report that they have succeeded in singling out and repressing stem-like cells in mouse breast tissue - cells that are widely thought to give rise to breast cancer.
Two studies from Mayo Clinic's site in Jacksonville, Fla., of women whose breast cancer spread to their brain, have found that women whose tumors do not have estrogen or progesterone receptors have the worst overall outcomes.
Breast tumors that are 1 centimeter in size or smaller - no more than 0.4 inch in length - can still be very aggressive and may require more intensive therapy than is routinely offered today
Agendia BV's MammaPrint breast cancer prognosis test was shown to be a valuable tool to assess risk of breast cancer recurrence also in post menopausal breast cancer patients.
Pivotal Phase 3 data show Denosumab increased bone density throughout skeleton in non-Metastatic Breast Cancer patients on adjuvant aromatase inhibitor therapy.
Anastrozole is more effective than tamoxifen at preventing breast cancer recurrence for periods of at least 10 years in women with hormone-responsive cancers. In addition, the increased risk of fractures that has been seen in some patients being treated with anastrozole disappears after treatment ends.
New data shows for the first time the predictive value of the 21-gene Recurrence Score (RS) assay in patients with node-positive breast cancer. The Breast Cancer Intergroup of North America trial conducted by the Southwest Oncology Group (SWOG 8814) originally showed that patients treated with 6 cycles of chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil followed by 5 years of tamoxifen (CAF-T) had superior disease-free survival (DFS) and overall survival (OS) compared with patients treated with tamoxifen alone.
Survey data also underscores dissatisfaction with breast cancer treatment experience, importance of internet as informational resource.
Monogram Biosciences presented the results of a study detailing the HERmark Assay's ability to identify metastatic breast cancer patients who are most likely to respond to Herceptin.
MammaPrint breast cancer prognosis test was successfully implemented in the diagnostic process of breast cancer patients in community hospitals in The Netherlands.
For women with early stage breast cancer treatment with the investigational chemotherapy combination of Taxotere Injection Concentrate and cyclophosphamide significantly improved overall survival.
Agendia makes its breast cancer prognosis test, MammaPrint, available to US patients.
Black women are not showing up for mammograms early and often enough, which contributes to a higher incidence of breast cancer and mortality rate from the disease.
MRI, which is not routinely administered to these patients, can find additional cancerous areas in the breast that previously evaded detection, discover cancer in the opposite breast that standard imaging tests such as mammography and ultrasound missed, or determine a tumor is actually larger than expected, the doctors say.
Breast cancer treatment drug Avastin does not appear to extend overall survival of breast-cancer patients and FDA will ask outside medical panel if Genentech's Avastin should be approved for breast cancer treatment.
Researchers have used PET imaging to see hyperactive cancer genes inside breast tumors in laboratory animals.
Researchers have uncovered the crucial role played by the enzyme focal adhesion kinase (FAK) in the onset of breast cancer.
American Association for Cancer Research says that breast cancer tumor diagnosis is slow in black women and in those ethnic minorities who may suffer from breast cancer.
A new model for calculating invasive breast cancer risk, called the CARE model, has been found to give better estimates of the number of breast cancers.
The formula used for the National Cancer Institute's Breast Cancer Risk Assessment Tool often underestimates the risk of cancer in older black women.
Patients prefer receiving a breast exam using the ARIA BIS over other modalities.
Researchers have developed a new breast cancer risk prediction model that more accurately estimates the breast cancer risk of African American women.
Minority women are more likely than white women to have severe pain related to metastatic breast cancer.